Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegafur. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegafur SCHEMBL28156468 | 0.90 | LMNA (0.94) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL7698456 | 0.90 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4553 | 0.90 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4552 | 0.90 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL8537231 | 0.90 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28851751 | 0.89 | LMNA (0.92) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL22320166 | 0.88 | LMNA (0.97) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4155129 | 0.88 | LMNA (0.97) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28304686 | 0.87 | LMNA (0.94) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10940658 | 0.86 | LMNA (0.91) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | claimed |
| JP-2011510632-A | — | — | 2011-04-07 | — | — | JP | claimed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | claimed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | claimed |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | US | disclosed |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | disclosed |
| US-8507656-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20110044998-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| US-20060121498-A1 | Enzymes involved in apoptosis | EIRX THERAPEUTICS LIMITED | 2006-06-08 | — | — | US | disclosed |
| EP-1601692-A2 | ENZYMES INVOLVED IN APOPTOSIS | Eirx Therapeutics Ltd (IE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078783-A2 | ENZYMES INVOLVED IN APOPTOSIS | EIRX THERAPEUTICS LIMITED (IE) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | TEK, VEGFA, THPO | LMNA 3971/4885MAPT 1708/4885ESR1 4391/4885 |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | TEK, VEGFA, THPO | LMNA 3971/4885MAPT 1708/4885ESR1 4391/4885 |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | TEK, VEGFA, THPO | LMNA 3971/4885MAPT 1708/4885ESR1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.